Novo Nordisk Lifts 2026 Guidance as the Wegovy Pill Sells Well

Novo Nordisk raised its 2026 adjusted sales and adjusted operating profit guidance to a range of +2% to -2% on November 4, 2026, after third-quarter profit beat forecasts (Reuters). The company said on its website that it had raised its full-year outlook after a stronger-than-expected third quarter, and that its Q3 results were out.

Guidance is a company's own forecast for the full year, a bit like a student's predicted grade before the final exam. Adjusted operating profit is the profit from the core business after certain one-off items are set aside.

The range is narrow and straddles zero. Its top end is growth of 2% and its bottom end is a decline of 2%, so the midpoint of the new outlook is roughly flat. The scale of the revision is easier to see against earlier forecasts. In February 2026, Novo Nordisk forecast that its 2026 profit and sales would fall by as much as 13%. In May, it said the worst drop would likely be 12%. The move from that February figure to the current range covers almost nine months of guidance changes, and the direction has been consistently upward.

The Wegovy pill was the most visible driver in the quarter. Reuters reported that the oral product beat third-quarter sales forecasts. Bloomberg had earlier reported that the Wegovy weight-loss pill generated revenue of 3.2 billion Danish kroner, in coverage published in August 2026 (Bloomberg). Oral semaglutide, the active ingredient in the pill, is the same drug family as the weekly Wegovy injection. The company's second-quarter investor presentation stated that oral semaglutide had been approved in the US and submitted in the EU, with an efficacy and safety profile broadly similar to Wegovy (Novo Nordisk).

The pipeline direction was already visible a year earlier. Novo Nordisk's Q3 2025 investor presentation said its US obesity portfolio would include CagriSema, Wegovy and oral semaglutide 25 mg (Novo Nordisk). The pill is now a commercial product rather than a planned one, and it is the main reason the guidance numbers have moved.

On the record, the chief executive spoke in September. Speaking to Reuters, he said weight-loss pills could capture as much as half of the global obesity drug market by 2030 (Reuters). Market share is the slice of total sales a product or company holds. This is a projection about market share, not a company target, and it carries the usual uncertainty of any long-range forecast.

In my view, the guidance raise and the pill figures together raise a question the headline numbers do not answer: how much of the pill's volume comes from new patients, and how much from people switching away from the Wegovy injection? The two groups bring in very different revenue per patient, and they affect the injectable business differently. Anyone modelling the mix has to make an assumption.

Bloomberg reported that Novo Nordisk's market value was about $215 billion in February, when the company forecast its steepest decline (Bloomberg).

The gap between a guided decline of as much as 13% and a range that now brackets zero is the core of the story for shareholders.

When reading coverage like this, it helps to keep three things apart. The guidance is a company statement. The pill sales beat is a reported quarterly outcome. The 50% market share figure is a chief executive's long-range projection.